Company profile
XTL BIOPHARMACEUTICALS LTD
NASDAQ:XTLBBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BICIFADINE | phase2 | — | 2 | terminated, unknown |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00597649 | phase2 | terminated | 2007-10-01 | 2008-12-01 | XTL Biopharmaceuticals | A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy |
| NCT00553592 | phase2 | unknown | 2007-09-01 | — | XTL Biopharmaceuticals | Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes |
| NCT00300807 | phase1 | unknown | 2005-10-01 | — | XTL Biopharmaceuticals | Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection |
FDA applications (0)
No records yet.